the results presented here suggested the significance of FKBP5 in chemoresistance and pancreatic cyst growth. More over, the data suggest that specific Akt inhibitors may be promising adjuvant therapies for pancreatic cancer, particularly in patients with lower-level of FKBP5. These studies Decitabine Dacogen may help individualize therapy to reach better treatment results for pancreatic cancer patients. The PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK cascades are often activated by genetic variations in upstream signaling molecules such as receptor tyrosine kinases. Targeting these pathways is usually complex and can end in activation with regards to the presence of upstream mutations RAF in the presence of mutant, triggered RAS and rapamycin can encourage Akt activation. Targeting with inhibitors inclined to two elements of the same pathway or two different signaling pathways may be a more efficient strategy. This review will first consider potential uses of MEK, Raf, PI3K, Akt and mTOR inhibitors Organism that have been investigated in clinical investigations and clinical and then talk about how cancers may become insensitive to different inhibitors and potential strategies to overcome this resistance. Recent studies have examined intensive panels of cell lines for mutations of genes implicated in cancer along with for their sensitivity to different inhibitors and chemotherapeutic drugs widely used to deal with cancers. The cell lines were analyzed by expression profiling, chromosome copy number, strong sequencing, biostatistical and systems studies. Both studies indicated that sensitivity to inhibitors was often related to genetic variations at important elements in a few other pathways, PI3K/PTEN/Akt/mTOR and the Ras/Raf/ MEK/ERK. One study has produced a Cancer Cell Line Encyclopedia which will be useful for predictive modeling of inhibitor sensitivity. Awareness to MEK and Raf inhibitors was usually examined Cabozantinib clinical trial in these studies. Sensitivity towards the T Raf inhibitor PLX4720 was proved to be highly related to specific strains at BRAF. Sensitivity to MEK inhibitors was demonstrated to be associated with BRAF, NRAS as well as PTEN, PTPN5, SPRY2, DUSP4, DUSP6 mutations and to a smaller extent mutations at KRAS. Sensitivity to MEK inhibitors in NRAS mutant lines was connected with aryl hydrocarbon receptor expression. Overview of Pathway Inhibitors Effective inhibitors specific for most of the essential aspects of the Ras/Raf/MEK/ERK and Ras/PI3K/ PTEN/mTOR paths have now been produced. Most of the time, these inhibitors have been evaluated in clinical trials. Furthermore, inhibitors that target the mutant protein significantly more than the wild-type protein of varied genes either have been or are being indicated. Therefore specific inhibitors have now been made and some are used in the hospital. Targeting some components of these pathways has proven clinically effective.